News

CAMBRIDGE, UK 30 March 2021 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the appointment of Michael Daniels, PhD, as Head of Product Management. In this role, Dr Daniels will be focused on the development and introduction of Evonetix’s first product, a DNA desktop writer.  He will work closely with the prospective customers and users of the Company’s products as well as the team’s engineers and research scientists.

AMSBIO, in association with Nordmark Biochemicals, is now offering animal-free Collagenase and Neutral Protease enzymes, isolated from Clostridium histolyticum, for in vitro tissue dissociation leading to high yields of viable cells.

Sioux Falls, South Dakota, United States and Cambridge, UK – 25 March 2021–Sanford Health (‘Sanford’), a leading US-based healthcare delivery system provider and Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples’ lives, today announce a genomics partnership focused on providing answers for patients and families with hard to diagnose rare diseases.

Cambridge, UK, 23 March 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable^®’ disease targets, today announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.